Barclays PLC Has $98,000 Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Barclays PLC trimmed its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 91.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,942 shares of the company’s stock after selling 125,931 shares during the period. Barclays PLC’s holdings in Ginkgo Bioworks were worth $98,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Algert Global LLC bought a new position in Ginkgo Bioworks during the second quarter worth $36,000. Wellington Wealth Strategies LLC. bought a new position in Ginkgo Bioworks during the second quarter worth $41,000. Thoroughbred Financial Services LLC bought a new position in Ginkgo Bioworks during the second quarter worth $70,000. Benjamin F. Edwards & Company Inc. boosted its position in Ginkgo Bioworks by 1,606.9% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 234,836 shares of the company’s stock worth $79,000 after purchasing an additional 221,078 shares during the period. Finally, Mackenzie Financial Corp bought a new position in Ginkgo Bioworks during the second quarter worth $251,000. 78.63% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, TD Cowen lifted their price objective on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, September 20th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $4.58.

Ginkgo Bioworks Stock Performance

Shares of Ginkgo Bioworks stock opened at $11.08 on Thursday. The company has a 50-day simple moving average of $8.99. The company has a market capitalization of $636.87 million, a PE ratio of -0.85 and a beta of 1.09. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $5.26 and a 52-week high of $64.40.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.